A prospective cohort study of clinical characteristics and outcomes in Chinese patients with estrogen receptor-negative/progesterone receptor-positive early breast cancer.

Yu FanXiaorong ZhongYu WangZhu WangTing LuoYanping WangHong Zheng

Published in: Breast cancer research and treatment (2023)

ER-/PR+ tumors have more aggressive pathological characteristics and more unfavorable clinical features than ER+ tumors. ET can reduce the LRR and mortality rates in ER-/PR+ patients. Postmenopausal and age ≥ 55 years ER-/PR+ patients can benefit from ET.

Keyphrases

estrogen receptor
end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
prognostic factors
breast cancer cells
cardiovascular disease
patient reported outcomes
metabolic syndrome
risk factors
type diabetes
coronary artery disease
insulin resistance
glycemic control
bone mineral density